Spire Wealth Management Increases Stake in Moderna, Inc. (NASDAQ:MRNA)

Spire Wealth Management lifted its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 2,150.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,224 shares of the company's stock after buying an additional 22,192 shares during the period. Spire Wealth Management's holdings in Moderna were worth $966,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the company. Blue Trust Inc. increased its stake in shares of Moderna by 365.6% in the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company's stock worth $49,000 after acquiring an additional 574 shares during the last quarter. Larson Financial Group LLC raised its stake in shares of Moderna by 53.5% in the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company's stock valued at $61,000 after acquiring an additional 317 shares during the period. Rakuten Securities Inc. lifted its holdings in shares of Moderna by 477.3% in the 3rd quarter. Rakuten Securities Inc. now owns 941 shares of the company's stock worth $63,000 after acquiring an additional 778 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its position in shares of Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after purchasing an additional 389 shares during the period. Finally, Brooklyn Investment Group acquired a new stake in Moderna in the 3rd quarter valued at approximately $80,000. Hedge funds and other institutional investors own 75.33% of the company's stock.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the firm's stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now directly owns 19,717 shares in the company, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last quarter, insiders have sold 2,664 shares of company stock valued at $115,210. 15.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Barclays lowered their price objective on shares of Moderna from $125.00 to $111.00 and set an "overweight" rating for the company in a research note on Friday, November 8th. Leerink Partners dropped their price target on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a research note on Thursday, January 16th. Jefferies Financial Group reduced their price target on Moderna from $65.00 to $55.00 and set a "hold" rating on the stock in a research report on Tuesday, October 15th. Evercore ISI lowered their target price on shares of Moderna from $60.00 to $50.00 and set an "in-line" rating for the company in a research note on Monday, January 27th. Finally, Berenberg Bank increased their price target on shares of Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a research note on Thursday, January 16th. Four analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $67.26.

Moderna Price Performance

Shares of MRNA stock traded down $1.01 during mid-day trading on Friday, reaching $32.60. The company's stock had a trading volume of 9,624,267 shares, compared to its average volume of 12,567,232. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The firm's 50-day moving average is $40.01 and its two-hundred day moving average is $58.25. Moderna, Inc. has a 1-year low of $31.94 and a 1-year high of $170.47. The company has a market cap of $12.55 billion, a P/E ratio of -5.60 and a beta of 1.59.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company's revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the business posted ($1.39) earnings per share. On average, research analysts predict that Moderna, Inc. will post -8.95 earnings per share for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.